Respuesta inmunológica a varias proteínas del H. pylori en pacientes guatemaltecos / Inmune response to various H. pylori proteins in Guatemalan patients

Se determinó la respuesta inmunológica a proteínas recombinantes de Helicobacter pylori en pacientes dis-pépticos (adultos y niños), pacientes con cáncer gástrico y sus familiares asintomáticos adultos viviendo con ellos. Se utilizó la prueba recomLine® Helicobacter IgG e IgA, y con base en el reconocimiento de los factores de virulencia VacA y CagA se determinó si la cepa de H. pylori era de tipo I o II. El análisis de los datos fue descriptivo y analítico y se estimaron los intervalos de confianza de 95%, con un nivel de error de 0.05 y Odds ratio. El 58.7% (121/206) de los pacientes presentó la bacteria en tinción histológica de biopsia, positividad que disminuyó con la edad y daño histológico. La frecuencia de la respuesta a los anticuerpos IgG fue mayor que IgA, en ambos casos ésta fue menor en los niños. Las proteínas del H. pylori más reconocidas tanto por IgA como IgG fueron VacA y CagA, y la respuesta a las otras proteínas investigadas fue mayor al aumentar el daño histológi-co. La cepa tipo I fue la que predominó en la población en estudio con 66% (136/206). Se deben continuar con los estudios de prevalencia de la cepa tipo I del H. pylori y del reconocimiento de sus antígenos en la población guatemalteca a fin de determinar su utilidad en el diagnóstico y pronóstico de la infección.

The immune response to recombinant Helicobacter pylori proteins was determined in dyspeptic patients (adults and children), patients with gastric cancer and their asymptomatic adults' relatives living with them. The recomLine® Helicobacter IgG and IgA test was used and based on the recognition of the virulence factors VacA and CagA, it was determined whether the H. pylori strain was type I or II. The data analysis was descriptive and analytic, and 95% confidence intervals were estimated, with an error level of 0.05, and Odds ratio. The patients that presented the bacterium in histological biopsy were 58.7% (121/206), positivity that decreased with age and histological damage. The frecuency of response to IgG antibodies was higher than IgA, in both cases it was lower in children. VacA and CagA were the H. pylori proteins most recognized by both IgA and IgG and it was observed that the number of recognized proteins was greater with increasing histological damage. The type I strain was the one that predominated in the study population 66% (136/206). Prevalence studies of the type I strain of H. pylori ant the recognition of its antigens in the Guatemalan population should continue in order to determine its usefulness in the diagnosis and prognosis of infection.

Influência da somatotropina recombinante bovina no desenvolvimento folicular e na coleta de embriões em éguas / Influence of bovine recombinant somatotropin in the follicular development and embryo colletion in mares

Dez éguas, sem raça definida, foram submetidas a avaliações ultrassonográficas durante o intervalo interovulatório, avaliando-se folículos ≥ 5mm. Cinco éguas foram tratadas com 500mg de r-bST no primeiro e no 14º dia pós-ovulação (grupo GT), e as demais com soro fisiológico (grupo GC). Quando o folículo dominante atingiu diâmetro ≥ 40mm, foram induzidas com hCG e inseminadas 24 horas após, sendo submetidas à coleta de embrião seis dias após a ovulação. Os dados foram agrupados de acordo com o diâmetro do folículo dominante nas fases de emergência, divergência, dominância, pré-ovulatória, indução, inseminação e ovulação. Todas as éguas foram usadas duas vezes, no mesmo grupo. O GT apresentou crescimento folicular precoce para as fases de emergência, divergência, dominância e pré-ovulatória, assim como para o seu maior folículo subordinado, que cresceu mais cedo. As taxas de recuperação foram de 90% (GC) e 70% (GT), em 16 estruturas coletadas, obtendo-se uma não fecundada e um blastocisto inicial para o grupo GC; os demais, no estágio de mórula, apresentaram comportamento semelhante entre os grupos. Conclui-se que a r-bST influencia a dinâmica folicular de éguas, levando a uma antecipação do desenvolvimento folicular, que pode ser utilizada para encurtar o ciclo estral.(AU)

Ten undefined mare breeds were submitted to ultrasonographic evaluations during the interovulatory interval, evaluating follicles measuring ≥ 5mm. Five mares were treated with 500mg r-bST on the first and the 14th day after ovulation (TG group), and the others with saline (CG group). When the dominant follicle reached a diameter ≥ 40mm the ovulation was induced with hCG, and the mares were inseminated 24 hours later and submitted to embryo collection six days after ovulation. The data were grouped according to the diameter of the dominant follicle in the emergence, divergence, dominance, preovulatory, induction, insemination and ovulation phases. All mares were used twice, in the same group. The GT showed early follicular growth for the emergence, divergence, dominance and pre-ovulatory phases, as well as for its greater subordinate follicle, growing earlier. The recovery rates were 90% (CG) and 70% (TG), and 16 structures were collected, obtaining an unfertilized embryo and an initial blastocyst for the CG group, the others in the morula stage behaved similarly between the groups. It can be concluded that r-bST influences the follicular dynamics of the mares, leading to an anticipation of the follicular development that can be used to shorten the estrous cycle.(AU)

Produção da proteína recombinante Interferon-ß1b na plataforma se síntese proteica livre de célula / Cell-free protein synthesis of recombinant Interferon-ß1b

Biofármacos e produtos imunobiológicos representam uma parcela significativa no mercado farmacêutico global. Cerca de 400 milhões de pessoas em todo o mundo dependem desses produtos e, muitas vezes, necessitarão delas para o resto de suas vidas. Até o momento, a tecnologia convencional para síntese dessas proteínas recombinantes é a expressão baseada em células. Porém, este sistema está frequentemente associado a problemas como a degradação da proteína-alvo devido à presença de nucleases e proteases, agregação com formação de corpos de inclusão e perda de molde de DNA. A plataforma de síntese proteica livre de células (do inglês Cell-Free Protein Synthesis ou CFPS) tem surgido como uma alternativa à expressão baseada em célula, permitindo a síntese de diversas proteínas, inclusive as de difícil expressão, na forma solúvel, em elevado rendimento e com capacidade de escalonamento. Este estudo buscou sintetizar a proteína interferon-ß1b humano recombinante (rhINF-ß1b) no sistema CFPS. Através de um trabalho de bioinformática, otimizou-se a sequência nucleotídica da proteína para expressão em lisado de E. coli e construiu-se um vetor de expressão linear, contendo promotor T7, RBS, região codificadora e um terminador T7. O sistema CFPS aceita molde de DNA no formato linear, que possui a vantagem de agilidade na preparação, sem a necessidade das etapas de clonagem, transformação, cultivo, extração e purificação do DNA. Também foi testado a expressão em DNA plasmidial, em que o gene do IFN foi clonado em vetor TOPO-TA Cloning. Para comparar os níveis de expressão foi utilizado esses mesmos vetores no sistema baseado em célula, com cepas de BL21(DE3) e Rosetta(DE3). Apesar da proteína de interesse não ter sido sintetizada com sucesso no sistema CFPS, foram dados alguns passos importantes para atingir este objetivo. No futuro, uma das prioridades é padronizar um sistema livre de células do laboratório capaz de fornecer um elevado rendimento para síntese de proteínas

Biopharmaceutical and immunobiological products represent a growing share of the global pharmaceutical market. Around 400 million people worldwide are dependent of such proteins and, often, they are going to need for the rest of their lives. So far, the most employed biopharmaceutical production technology is cell-based expression. However, this system is usually associated with problems such as degradation of proteins due to the presence of endogenous nucleases or proteases, aggregation with inclusion bodies formation and loss of DNA template. Cell-Free Protein Synthesis (CFPS) platform has emerged as an alternative to cell-based expression, allowing synthesis of many types of proteins, including difficult-to-express proteins, proteins in soluble form, in high yield and possibility to scale up or down the process. This work sought to synthesize recombinant human interferon-ß1b (rhINF-ß1b) in CFPS system. Through a bioinformatics study, a nucleotide sequence of the target protein was optimized for expression in E. coli lysate and a linear DNA template was designed, containing a T7 promoter, a RBS, a coding sequence and a T7 terminator. The CFPS system accepts linear template DNA, which has the advantage of agility in the preparation, without the need for the steps of cloning, transformation, cultivation, extraction and purification of DNA template. Expression in plasmid DNA was also tested, wherein the IFN gene was cloned into TOPO-TA Cloning vector. To compare expression levels, the same vectors were used in the cell-based system with BL21 (DE3) and Rosetta (DE3) strains. Although the protein of interest was not successfully synthesized in the CFPS system, some important steps were taken to achieve this goal. In the future, one of the priorities is to standardize the lysate preparation for a high throughput protein production

Avaliação da imunogenicidade de diferentes formas alélicas da proteí­na recombinante PvAMA-1expressa em Pichia pastoris: impacto da diversidade antigênica / Evaluation of the immunogenicity of different allelic forms of PvAMA-1 protein expressed in Pichia pastoris: impact of antigenic diversity

A malária é um problema de saúde pública no Brasil e no mundo. Em 2016, o número de casos estimado pela Organização Mundial de Saúde foi de 216 milhões. Plasmodium falciparum é a espécie mais prevalente e responsável pelo maior número de mortes no mundo, sobretudo no continente africano. Por outro lado, o Plasmodium vivax é conhecido por sua ampla distribuição geográfica, sendo a espécie que predomina nas Américas, incluindo o Brasil. Nos últimos 20 anos, nosso grupo tem gerado e caracterizado diversas proteínas recombinantes baseadas em antígenos imunodominantes de P. vivax que podem servir como base para o desenvolvimento de uma vacina contra malária. Entre os antígenos de merozoítas, uma das principais proteínas em estudo pelo nosso grupo é o Antígeno 1 de Membrana Apical de P. vivax (PvAMA-1), caracterizado previamente como altamente imunogênico em infecções naturais e em camundongos imunizados, na presença de diferentes adjuvantes. O objetivo do presente estudo foi investigar o efeito da diversidade antigênica dessa proteína no reconhecimento por anticorpos específicos e na indução de imunidade contra o parasita. Para isso, foram geradas seis novas proteínas representando diferentes alelos descritos na natureza: PvAMA-1-Belem, PvAMA-1-Sal-I, PvAMA-1-Chesson-I, PvAMA-1-SK0814-apical, PvAMA-1-Indonesia-XIX e PvAMA-1-PNG_62_MU. As proteínas recombinantes foram expressas em leveduras Pichia pastoris e purificadas em duas etapas cromatográficas. Em seguida, as imunizações em camundongos C57BL/6 foram realizadas com as proteínas administradas de forma isolada, ou em combinação, na presença do adjuvante agonista de TLR3 (Poly I:C). Por ELISA, observamos que todas as formulações foram capazes de induzir anticorpos IgG contra as proteínas homólogas e heterólogas, o que sugere que a diversidade antigênica entre as formas alélicas não compromete o reconhecimento. Os dados gerados no presente trabalho sugerem que uma formulação contendo mistura de diferentes alelos representando a proteína AMA-1 pode ser explorada para o desenvolvimento de uma vacina de ampla cobertura contra o P. vivax

Malaria is a public health problem in Brazil and throughout the world. In 2016, the World Health Organization estimated there were 216 million cases of malaria. Plasmodium falciparum is the most prevalent species and is responsible for the largest number of deaths, especially in the African continent. However, Plasmodium vivax is known for its wide geographic distribution, being the species that prevails in the Americas, including Brazil. In the last 20 years, our group has generated and characterized several recombinant proteins based on immunodominant antigens of P. vivax that can serve as a basis for the development of a malaria vaccine. Among the merozoite antigens, one of the main proteins studied by our group is P. vivax apical membrane antigen-1 (PvAMA-1), previously characterized as highly immunogenic in natural infections and immunized mice, in the presence of different adjuvants. The objective of this study was to investigate the effect of antigenic diversity of this protein in the recognition of specific antibodies and the induction of immunity against the parasite. For this, six new proteins were generated representing different alleles described in nature: PvAMA-1-Belem, PvAMA-1-Sal-i, PvAMA-1-Chesson-i, PvAMA-1-SK0814-apical, PvAMA-1-Indonesia-XIX, and PvAMA-1-PNG_62_MU. Recombinant proteins were expressed in Pichia pastoris yeast and purified by two chromatographic stages. Then, C57BL/6 mice were immunized with these proteins administered in isolation or in combination, in the presence of the TLR3 agonist adjuvant, Poly I:C. Using an enzyme-linked immunosorbent assay, we observed that all formulations induced IgG antibodies against homologous and heterologous proteins. This indicates that antigenic diversity between allele forms does not compromise recognition. This finding suggests that a formulation containing a mixture of different alleles representing the PvAMA-1 protein can be exploited for developing of a wide coverage vaccine against P. vivax

Development of an indirect ELISA based on recombinant capsid protein to detect antibodies to bovine leukemia virus

Abstract Serological testing and culling infected animals are key management practices aiming eradication of bovine leukemia virus infection. Here, we report the development of an indirect ELISA based on BLV recombinant capsid protein (BLVp24r) to detect anti-BLV antibodies in cattle serum. The BLVp24r was expressed in Escherichia coli and purified by affinity chromatography, and then used to set up the ELISA parameters. The Polysorp ® plate coated with 50 ng of antigen/well and bovine serum diluted 1:100 gave the best results during standardization. Using sera from infected and non-infected cattle we set up the cutoff point at 0.320 (OD450 nm) with a sensitivity of 98.5% and specificity of 100.0%. Then, we tested 1.187 serum samples from dairy (736 samples) and beef cattle (451 samples) with unknown status to BLV. We found that 31.1% (229/736) and 9.5% (43/451) of samples amongst dairy and beef cattle, respectively, had IgGs to BLV. The rate of agreement with a commercial competitive ELISA was 84.3% with a κ value of 0.68. Thus, our BLVp24r iELISA is suitable to detect BLV infected animals and should be a useful tool to control BLV infection in cattle.

Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile

Abstract Clostridium difficile has emerged as an increasingly important nosocomial pathogen and the prime causative agent of antibiotic-associated diarrhoea and pseudomembranous colitis in humans. In addition to toxins A and B, immunological studies using antisera from patients infected with C. difficile have shown that a number of other bacterial factors contribute to the pathogenesis, including surface proteins, which are responsible for adhesion, motility and other interactions with the human host. In this study, various clostridial targets, including FliC, FliD and cell wall protein 66, were expressed and purified. Phage antibody display yielded a large panel of specific recombinant antibodies, which were expressed, purified and characterised. Reactions of the recombinant antibodies with their targets were detected by enzyme-linked immunosorbent assay; and Western blotting suggested that linear rather than conformational epitopes were recognised. Binding of the recombinant antibodies to surface-layer proteins and their components showed strain specificity, with good recognition of proteins from C. difficile 630. However, no reaction was observed for strain R20291—a representative of the 027 ribotype. Binding of the recombinant antibodies to C. difficile M120 extracts indicated that a component of a surface-layer protein of this strain might possess immunoglobulin-binding activities. The recombinant antibodies against FliC and FliD proteins were able to inhibit bacterial motility.

Expression of a recombinant protein, A2 family, from Leishmania infantum (Jaboticabal strain) and its evaluation in Canine Visceral Leishmaniasis serological test / Expressão de uma proteína recombinante, da família A2, de Leishmania infantum (amostra Jaboticabal) e sua avaliação no teste sorológico da Leishmaniose Visceral Canina

This study aimed to express a recombinant A2 family protein of Leishmania chagasi, Jaboticabal strain; test this protein as an antigen in serological assays; and investigate its antigenicity and immunogenicity. A protein coded by an allele of the A2 gene isolated from L. chagasi was expressed in three different strains of Escherichia coli. We used 29 sera samples from Leishmune-vaccinated dogs, 482 sera samples from dogs from endemic areas (positive controls), and 170 sera samples from dogs from non-endemic areas (negative controls) in ELISA tests using soluble Leishmaniaantigen (SLA) and His-A2 as antigen. Expressed proteins showed, by western blotting, the expression of an 11 KDa protein. Sixty-three percent (303/482) of the samples from endemic areas were positive by ELISA His-A2, whereas 93.1% (27/29) of Leishmune®-vaccinated animals were negative by His-A2-ELISA. Anti-A2 antibodies from mice inoculated with the A2 protein were detected in slides containing amastigote forms, but not in slides containing promastigote forms. The A2 recombinant protein from L. chagasi may be a useful tool in the diagnosis of CVL, and further tests regarding the infection stage and the specie of parasite at which the dogs are sampled should provide a better understanding of our results.

Este estudo teve como objetivos expressar uma proteína recombinante da família A2 de Leishmania chagasi, amostra de Jaboticabal-SP; testar essa proteína como antígeno em testes sorológicos; e investigar a antigenicidade e imunogenicidade dessa proteína. Uma proteína codificada por um alelo do gene A2 isolado de L. chagasi foi expressa em três diferentes amostras de Escherichia coli. Foram utilizadas 29 amostras de soro de cães vacinados com Leishmune, 482 amostras de soro de cães de áreas endêmicas (controles positivos), e 170 amostras de soro de cães de áreas não-endêmicas (controles negativos) no ELISA-teste utilizando-se antígeno solúvel total de Leishmania (AST) e His-A2 como antígenos. As proteínas expressas, detectadas pelo western blotting, mostraram a expressão de uma proteína de 11 KDa. Sessenta e três por cento (303/482) das amostras de áreas endêmicas foram positivas pelo ELISA-teste, utilizando-se antígeno His-A2; e 93,1% (27/29) dos animais vacinados com a Leishmune foram negativos. Anticorpos anti-A2 de camundongos inoculados com a proteína A2 foram detectados em lâminas contendo formas amastigotas, enquanto em lâminas contendo formas promastigotas não houve detecção de anticorpos anti-A2. A proteína recombinante A2 pode ser uma ferramenta útil no diagnóstico da LVC, e maiores estudos sobre o estágio de infecção e a espécie de parasita dos cães amostrados devem prover melhor entendimento dos resultados encontrados.

Growth inhibition of Staphylococcus aureus and escherichia coli strains by neutralizing IgY antibodies from ostrich egg yolk

Ostrich raising around the world have some key factors and farming profit depend largely on information and ability of farmers to rear these animals. Non fertilized eggs from ostriches are discharged in the reproduction season. Staphylococcus aureus and Escherichia coli are microorganisms involved in animal and human diseases. In order to optimize the use of sub products of ostrich raising, non fertilized eggs of four selected birds were utilized for development of polyclonal IgY antibodies. The birds were immunized (200ug/animal) with purified recombinant staphylococcal enterotoxin C (recSEC) and synthetic recRAP, both derived from S. aureus, and recBFPA and recEspB involved in E. coli pathogenicity, diluted in FCA injected in the braquial muscle. Two subsequent immunization steps with 21 days intervals were repeated in 0,85% saline in FIA. Blood and eggs samples were collected before and after immunization steps. Egg yolk immunoglobulins were purified by precipitation with 19% sodium sulfate and 20% ammonium sulphate methodologies. Purified IgY 50µL aliquots were incubated in 850µL BHI broth containing 50µL inoculums of five strains of S. aureus and five strains of E.coli during four hours at 37ºC. Growth inhibition was evaluated followed by photometry reading (DO550nm). Egg yolk IgY preparation from hiperimmunized birds contained antibodies that inhibited significantly (p<0,05) growth of strains tested. Potential use of ostrich IgY polyclonal antibodies as a diagnostic and therapeutic tool is proposed for diseased animals.

Response surface methodology of nitrilase production by recombinant Escherichia coli

Growth and nitrilase production by recombinant Escherichia coli cells harbouring pET 21 (b) plasmid, for the expression of Pseudomonas putida nitrilase were improved using response surface methodology. Central composite design was used for obtaining ideal concentration of critical medium components which include fructose, tryptone, yeast extract and lactose. The optimal values for the concentration of fructose, tryptone, yeast extract and lactose were found to be 1.13, 2.26, 3.25 and 0.9 percent (w/v), respectively. Here, fructose served as carbon source for the growth while lactose was preferably used as inducer for the expression of foreign protein. Yeast extract in the medium was used as a growth promoter while tryptone was added as a major nitrogen source. Using this optimized medium, an experimental growth of 6.67 (OD at 600 nm) and nitrilase activity of 27.13 U/ml was achieved. This approach for medium development led to an enhancement of the growth and enzyme activity by 1.4 and 2.2 times, respectively, as compared to the un-optimized medium.

Biochemical characterization of a calcium-sensitive protein kinase LeCPK2 from tomato.

LeCPK2 (GenBank GQ205414), a versatile calcium-dependent protein kinase (CDPK or CPK) gene was isolated from tomato in our previous study. In this study, the biochemical properties of LeCPK2 were further investigated. To examine the role of the C-terminal calmodulin-like domain (CLD) of LeCPK2 with respect to Ca2+ activation, the kinase activities of recombinant full-length and truncated LeCPK2 were measured by Kinase-Glo® Luminescent kinase assay (Promega). The results showed that LeCPK2 activity was Ca2+-dependent and the C-terminal CLD of 161 residues was essential for the activation of LeCPK2. The activity of LeCPK2 was sharply stimulated by Ca2+ with K0.5 (concentration of Ca2+ for half-maximal activity) of 48.8 and 45.5 nM with substrate histone IIIs and syntide 2, respectively. The optimal concentration of Mg2+ for LeCPK2 activity was 20 and 10 mM for substrate histone IIIs and syntide 2, respectively. The Km value of LeCPK2 towards histone IIIs and syntide 2 was 44.9 μg/ml and 89.52 μM, respectively. The determination of biochemical properties of LeCPK2 would provide some clues on how its activity was regulated in vivo.

Production of recombinant EMA-1 protein and its application for the diagnosis of Theileria equi using an enzyme immuno assay in horses from São Paulo State, Brazil / Produção da proteína recombinante EMA-1 e sua aplicação para o diagnóstico baseadono imuno ensaio enzimático de Theileria equi em equinos do Estado de São Paulo, Brasil

The erythrocytic-stage surface protein, Equi Merozoite Antigen 1 (EMA-1), is a major candidate for the development of a diagnostic antigen for equine piroplasmosis. In order to establish an effective diagnostic method for practical use, the gene encoding the entire EMA-1 of Theileria equi Jaboticabal strain was cloned and expressed in Escherichia coli as a histidine-tagged protein (His6-EMA1). The expressed EMA-1 reacted with specific antibodies in Western blot and had an apparent molecular mass of 34 kDa which was largely consistent with its theoretical value. The nucleotide sequence of the EMA-1 gene of Jaboticabal strain was comparatively analyzed with other published sequences. The results indicated a high degree of homology with EMA-1 genes of all other strains isolated from various countries. The recombinant purified His6-EMA1 protein was tested in an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies anti-T. equi in horses. The ELISA clearly differentiated T. equi-infected from Babesia caballi-infected horse sera or normal horse sera. Field serum samples collected from horses in the State of São Paulo, Southeastern Brazil, were examined for the diagnosis of T. equi infection by ELISA. Of 170 samples analyzed, 95.88 percent (163/170) were positive for T. equi infection. These results suggest that the His6-EMA1 protein expressed in E. coli could be a reliable immunodiagnostic antigen for ELISA test and that T. equi infection is a serious concern in the State of São Paulo, Brazil.

A proteína de superfície eritrocitária, Antígeno 1 do Merozoíta de Theileria equi (EMA-1), é um potencial candidato para o desenvolvimento de antígenos de valor diagnóstico para a piroplasmose equina. Com o objetivo de estabelecer um método de diagnóstico efetivo e prático, o gene EMA-1 da amostra Jaboticabal - SP de T. equi foi clonado e expresso em Escherichia coli contendo uma cauda de poli-histidina (His6-EMA1). O EMA-1 expresso reagiu com anticorpos específicos no Western blot e apresentou peso molecular aparente de 34 kDa, sendo altamente consistente com seu valor teórico. A sequência nucleotídica do gene EMA-1 da amostra Jaboticabal foi analisado comparativamente com outras sequências públicas, e os resultados indicam elevado grau de homologia com amostras de diversos países. A proteína recombinante purificada His6-EMA1 foi testada no ensaio imunoenzimático (ELISA) para a detecção de anticorpos anti-T. equi em equinos. O teste de ELISA diferenciou-se claramente entre soros de equinos infectados por T. equi, soros de animais infectados por Babesia caballi e soro normal de equino. Amostras de soros coletadas de equinos do Estado de São Paulo, sudeste do Brasil, foram examinadas para o diagnóstico da infecção por T. equi pelo ELISA. Das 170 amostras analisadas, 95,88 por cento (163/170) foram positivas para T. equi. Os resultados sugerem que a proteína His6-EMA1 expressa em E. coli pode ser um antígeno confiável para diagnóstico imunológico pelo teste de ELISA, e que T. equi merece grande atenção no Estado de São Paulo.

The Effects of Anti-insulin Antibodies and Cross-reactivity with Human Recombinant Insulin Analogues in the E170 Insulin Immunometric Assay / 대한진단검사의학회지

BACKGROUND: Insulin assays are affected by varying degrees of interference from anti-insulin antibodies (IAs) and by cross-reactivity with recombinant insulin analogues. We evaluated the usefulness of the E170 insulin assay by assessing IA effects and cross-reactivity with 2 analogues. METHODS: Sera were obtained from 59 type 2 diabetes patients receiving continuous subcutaneous insulin infusion and 18 healthy controls. Insulin levels were determined using an E170 analyzer. To investigate the effects of IAs, we performed IA radioimmunoassays, and analyzed the differences between directly measured insulin (direct insulin) and polyethylene glycol (PEG)-treated insulins (free, IA-unbound; total, IA-bound and unbound insulin). We performed in-vitro cross-reactivity tests with insulin aspart and insulin glulisine. RESULTS: In IA-positive patients, E170 free insulin levels measured using the E170 analyzer were significantly lower than the direct insulin levels. The mean value of the direct/free insulin ratio and IA-bound insulin, which were calculated as the difference between total and free insulin, increased significantly as endogenous IA levels increased. The E170 insulin assay showed low cross-reactivities with both analogues (< 0.7%). CONCLUSIONS: IAs interfered with E170 insulin assay, and the extent of interference correlated with the IA levels, which may be attributable to the increase in IA-bound insulin, and not to an error in the assay. The E170 insulin assay may measure only endogenous insulin since cross-reactivity is low. Our results suggest that the measurement of free insulin after PEG pre-treatment could be useful for beta cell function assessment in diabetic patients undergoing insulin therapy.

Extension model of lactation curves to evaluate the effect of the recombinant bovine somatotropin on milk yield in Holstein cows / Modelo de extensão de curvas de lactação para avaliar o efeito da somatotropina bovina recombinante sobre a produção de leite em vacas Holstein

An extension model of lactation curves was used to determine the effect of recombinant bovine somatotropin (bST-r) on milk yield in Holstein dairy cattle. This model use the fitted values obtained by the Wood model, and was tested on the records of 66 cows. The milk yield predicted with the extension model and the observed yield were compared and no significant differences were observed (P>0.05). Once the extension model was validated, the milk yield tests of 199 cows were used. The cows received bST-r 500mg by subcutaneous injections. The injections were applied after 100 days in milk at 14-day intervals (seven injections). The observed milk yield was compared with the yield expected by the extension model. An increase of 5.3 percent was observed in milk yield in response to the bST-r. This increase is lower than that reported in the literature in response to the growth hormone in dairy cattle. It is concluded that extension model used in the present work is reliable for extending the lactation curve in Holstein cows, and the increase in milk yield in response to the application of bST-r, determined in the same animal using the extension model, was lower than that reported by other authors.

Um modelo de extensão de curvas de lactância foi utilizado para determinar o efeito da somatotropina bovina recombinante (bST-r) sobre a produção de leite em vacas Holstein. Este modelo, que utiliza os valores ajustados obtidos pelo modelo de Wood, foi testato nos registros de 66 vacas. A produção de leite predita com o modelo de extensão e a produção observada foram comparadas e não se observaram diferenças significativas (P>0,05). Uma vez validado o modelo de extensão, utilizaram-se os controles de produção de leite (de cada 15 dias) de 199 vacas. As vacas receberam injeções de 500mg de bST-r via subcutânea. As injeções fora aplicadas a partir dos 100 dias de lactação a intervalos de 14 dias (sete injeções). A produção de leite observada foi comparada com a produção esperada com o modelo de extensão. Observou-se um incremento de 5,3 por cento na produção de leite em resposta à bST-r. Este incremento foi menor que o relatado na literatura em resposta ao hormônio do crescimento em vacas leiteiras. O modelo de extensão usado é confiável para estender a curva de lactação na vaca Holstein, e o aumento do rendimento de leite em resposta à aplicação de bST-r, determinado no mesmo animal usando o modelo de extensão, foi inferior ao observado por outros autores.

Obtenção de proteína recombinante baseada em antígenos do líquido vesicular de Taenia crassiceps: aplicação no imunodiagnóstico da neurocisticercose / Recombinant protein obtainment based on antigens from Taenia crassiceps vesicular fluid: application on immunodiagnostics of neurocisticercosis

A neurocisticercose (NC) é uma doença provocada por larvas de Taenia solium (Tso) no sistema nervoso central. Seu diagnóstico fundamenta-se em critérios clínicos, epidemiológicos e laboratoriais. A utilização de antígenos parasitários no imunodiagnóstico apresenta desvantagens como: necessidade de animais, ausência de homogeneidade entre lotes, baixo rendimento, e contaminação com proteínas suínas. Assim, os antígenos recombinantes podem otimizar o imunodiagnóstico da NC, pois são reagentes simples e reprodutíveis, sem requerer animais. Este estudo teve como objetivo a obtenção, caracterização e análise da reatividade de proteína recombinante baseada em antígenos de líquido vesicular de Taenia crassiceps (Tcra). Assim, o cDNA foi obtido por amplificação a partir de RNAm de cisticercos de Tcra. A proteína recombinante Tc14 foi produzida em Escherichia coli (DE3) BL21 utilizando-se o vetor de expressão pET-22b e purificada por cromatografia de afinidade. A caracterização antigênica deu-se por Imunoblot (IB) utilizando anticorpos monoclonais (AcMo). Houve reatividade com todos os AcMo utilizados (AcMo anti-antígeno de excreção/secreção de Tcra, AcMo anti-líquido vesicular de Tcra, AcMo antilíquido vesicular de Tso e AcMo anti-antígeno total de Tso), exceto com o AcMo anti-antígeno de escólex de Tso. Utilizando-se 22 amostras de soro e 19 de líquor (LCR) de pacientes com NC, 48 soros e 28 LCR do grupo controle negativo (GCN) e 17 soros de hidatidose do grupo outras parasitoses (OP) em Imunoblot foi observada reatividade na região de 14kDa, correspondente a Tc14, em todas as amostras NC, mas não nos GCN e OP. Em ELISA com Tc14 obteve-se sensibilidade (S) e especificidade (E) de 100% com LCR (29 amostras de NC e 35 do GCN) e S de 95,1% e E de 100% com soro (41 amostras de NC, 52 do GCN). Dentre 51 soros de OP, mostraram-se reagentes um de hidatidose e outro de estrongiloidíase. A análise comparativa entre diferentes antígenos e testes sorológicos apresentou índice...

The neurocisticercosis (NC) disease is caused by the presence of Taenia solium (Tso) larvae in the central nervous system. Its diagnosis is based on clinical criteria, epidemiological studies and laboratorial exams. Nevertheless, the use of parasite antigenic extracts into the immunodiagnosis presents some disadvantages: it requires animals, lacks of homogeneity between lots, low yield and may become contaminated with swine proteins. Consequently, the utilization of recombinant antigens could optimize the immunodiagnostic of NC, as they are simple and reproducible reagents that do not require animals. This study aimed the capture, characterization and reactivity analysis of the recombinant protein based on antigens of the vesicular fluid of Taenia crassiceps (Tcra). In order to do so, the cDNA was obtained through the amplification deriving from RNAm of cysticerci of Tcra. The recombinant protein Tc14 was produced in Escherichia coli (DE3) BL21 using the expression vector pET-22b and purified by affinity chromatography (nickel resin). The antigenic characterization was performed by immunoblotting (IB) using monoclonal antibodies (MoAb). The recombinant protein presented reactivity with all the MoAb used (Anti-secretion/excretion antigens from Tcra MoAb, anti-vesicular fluid from Tcra MoAb, anti-vesicular fluid from Tso MoAb and anti- total antigen from Tso MoAb), except with the anti-antigen from Tso scolex MoAb. The immunoblot was performed using 22 serum samples and 19 cerebrospinal fluid (CSF) from patients with NC, 48 serum and 28 CSF from the negative control group (GCN) and 17 hydatidosis serum from other parasitosis' group (OP). It showed reactivity in the 14kDa region, correlated to Tc14, in all NC samples, but not presented on GCN and OP. In ELISA with Tc14, the sensibility (S) and specificity (E) of 100% was obtained with CSF (29 NC samples and 35 GCN samples) and 95.1% of S and 100% of E with serum (41 NC samples, 52 GCN samples)...

Cloning and expression of trypsin-encoding cDNA from Blattella germanica and its possibility as an allergen

In this study, the trypsin gene (bgtryp-1) from the German cockroach, Blattella germanica, was cloned via the immunoscreening of patients with allergies to cockroaches. Nucleotide sequence analysis predicted an 863 bp open reading frame which encodes for 257 amino acids. The deduced amino acid sequence exhibited 42-57% homology with the serine protease from dust mites, and consisted of a conserved catalytic domain (GDSGGPLV). bgtryp-1 was determined by both Northern and Southern analysis to be a 0.9 kb, single-copy gene. SDS-PAGE and Western blotting analyses of the recombinant protein (Bgtryp-1) over-expressed in Escherichia coli revealed that the molecular mass of the expressed protein was 35 kDa, and the expressed protein was capable of reacting with the sera of cockroach allergy patients. We also discussed the possibility that trypsin excreted by the digestive system of the German cockroach not only functions as an allergen, but also may perform a vital role in the activation of PAR-2.

Characterization of the Recombinant Proteins of Porcine Circovirus Type2 Field Isolate Expressed in the Baculovirus System

Porcine circovirus (PCV) type2 was isolated using primary porcine kidney cells from lymph node of piglets with typical PMWS. The presence of the virus was identified by PCR using primers specific to PCV type2. The ORFs 1 and 2 were amplified by PCR using primers corresponding to the target genes of the PCV type 2. Cloned genes were inserted into the baculovirus expression vector and PCV recombinant proteins were expressed using baculovirus expression system. Recombinant protein expression was determined by indirect immunofluorescent assay (IFA) and immunoblotting using polyclonal antiserum to PCV. ORF1 gene expressed two proteins with approximately 17 kDa and 31 kDa proteins in the baculovirus system. Recombinant protein of the ORF2 was similar to that of the native virus except minor bands with different molecular weight were detected. Recombinant protein expressed in the baculovirus system showed at least two glycosylation sites based on the tunicamycin treatment. Recombinant protein of the ORF2 assembled virus-like particle in recombinant virus infected insect cells.

Construção e análise de mutantes fluorescentes da troponina I / Construction and analysis of Troponin I fluorescence mutants

A troponina (Tn) regula a contração do músculo estriado esquelético de vertebrados. Ela é composta de três subunidades: troponina I (TnI), troponina C (TnC) e troponina T (TnT). A TnI tem a função inibitória que é neutralizada pela ligação de Ca²+ nos sítios regulatórios do N-domínio da TnC, e a TnT posiciona o complexo no filamento fino. Para monitorar o sinal do Ca²+ sendo transmitido da TnC para a TnI as propriedades espectrais únicas do 5-hidroxitriptofano (5HW) foram utilizadas. O 5HW foi incorporado em mutantes pontuais da TnI com um único códon para triptofano. Foram identificadas duas sondas espectrais intrínsicas na TnI capazes de detectar a ligação de Ca²+ na Tn: as TnIs com 5HW nas posições 100 e 121...

Proteínas recombinantes da saliva de triatoma infestans / Recombinant proteins of the saliva in triatoma infestans

Insetos hematófagos transmitem doenças ao contaminar a presa durante o repasto. Acredita-se que um longo processo de evolução teria feito com que tais insetos acumulassem na secreção salivar uma gama de compostos que facilitariam a obtenção do sangue...

Transferencia de insulinas en 198 pacientes de seis países latinoamericanos / Transference of insulins in 198 patients of six Latinoamerican countries

Es un estudio multicéntrico, comparativo, ciego, aleatorio y prospectivo que evaluó la eficacia y seguridad de la transferencia de insulinas de origen animal a insulina humana biosintética en 198 pacientes de seis países latinoamericanos. Todos los pacientes recibían insulinas de origen animal al menos dos meses antes de su inclusión al estudio. Este tuvo una duración de seis semanas, con evaluaciones al inicio, y a las dos y seis semanas. La eficacia se determinó por cambios inicial-final en la glucemia de ayunas y hemoglobina glucosilada, y la seguridad por la aparición de efectos adversos. De los 198 pacientes, 94 se asignaron al grupo de insulina bovina y 104 al de humana. Al ingreso, ambos grupos fueron similares en sus características. El único cambio al final del estudio fue una disminución en la glucemia en ayunas en el grupo de insulina humana (bovina 212 ñ 95.3 vs 193 ñ 78.8 mg/dL, p= 0.18; humana 198 ñ 86.8 vs 169 ñ 71.7, p= 0.025). El resto de los parámetros no tuvieron modificaciones estadísticamente significativas, aunque la tendencia fue hacia la mejoría en las cifras de hemoglobina glucosilada en ambos grupos. Se presentaron episodios de hipoglucemia leve con mayor frecuencia en el grupo de insulina humana, y hubo un episodio de hipoglucemia grave sin síntomas premonitorios con insulina humana. Concluimos que la transferencia de insulina de origen animal a insulina humana biosintética, en pacientes diabéticos insulinorrequirientes latinoamericanos, es eficaz y razonablemente segura (con ajuste de las dosis de insulina al hacer el cambio)